anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Enhancement of Connexin43 (Cx43) and ferroptosis are respectively associated with the exacerbation of myocardial ischemia-reperfusion injury (MIRI) in diabetes. Myocardial vulnerability to ischemic insult has been shown to vary during early and later phases of diabetes in experimental settings. Whether or not Connexin43 (Cx43) and ferroptosis interplay during MIRI in diabetes is unknown. We, thus, aimed to investigate whether or not the content of myocardial Cx43 may be attributable to myocardial vulnerability to MIRI at different stages of diabetes and also to explore the potential interplay between Cx43 and ferroptosis in this pathology. Age-matched control and subgroups of Streptozotocin-induced diabetic mice were subjected to MIRI induced by 30 minutes coronary artery occlusion and 2 hours reperfusion respectively at 1, 2 and 5 weeks of diabetes. Rat cardiac H9C2 cells were exposed to high glucose (HG) for 48h in the absence or presence of Cx43 gene knockdown followed by hypoxia/reoxygenation (HR) respectively for 6 and 12 hours. Post-ischemic myocardial infarct size was reduced in 1 and 2 weeks DM mice concomitant with enhanced GPX4 and reduced cardiac Cx43 and ferroptosis as compared to control. By contrast, cardiac GPX4 was significantly reduced while Cx43 increased at DM 5 weeks (D5w) which was correspondent to significant increases in ferroptosis and myocardial infarction. Post-ischemic cardiac function was improved in 1 and 2 weeks but worsened in 5w DM mice as compared with non-diabetic control. GAP19 (Cx43 inhibitor) significantly attenuated ferroptosis and reduced myocardial infarction in D5w mice. Erastin (ferroptosis activator) reversed the cardioprotective effect of GAP19. In vitro, HR significantly reduced cell viability accompanied with reduced GPX4 but elevated Cx43 expression, MDA production and ferroptosis. Cx43 gene knockdown in H9C2 resulted in a significant increase in GPX4, reduction in MDA and ferroptosis, and subsequently reduced post-hypoxic cell viability. The beneficial effects of Cx43 gene knock-down was minified or eliminated by Erastin. It is concluded that Cx43 overexpression exacerbates MIRI under diabetic conditions via promoting ferroptosis, while its down-regulation at early state of diabetes is attributable to enhanced myocardial tolerance to MIRI.
FIELD: medicine. SUBSTANCE: method involves applying malignant tumor gene- suppressor agents in combination with a DNA-affecting agents or factor to kill cells being in particular cases malignant tumor cells. Malignant tumor gene-suppressor p53 is in vivo delivered by a gene-carrier with adenovirus recombinant as intermediate stage in combination with a chemotherapeutic agent. Treated cells show apoptosis state with specific DNA-fragmentation. Direct subcutaneous injection of a p53-adenovirus formulation into malignant tumors with following DNA-affecting agent like cis-platinum intraperitoneal administration causes general scale apoptotic tumor destruction. The method also involves causing gene displacement due to replication-defective adenovirus p53 of wild-nature type being applied in combination with DNA-affecting agents for treating the cases of malignant tumors. EFFECT: enhanced effectiveness of treatment. 115 cl, 45 dwg
Historically, specific mutations in WT1 gene have been associated with distinct syndromes based on phenotypic characteristics, including Denys-Drash syndrome (DDS), Frasier syndrome (FS), Meacham syndrome, and WAGR syndrome. DDS is classically defined by the triad of steroid-resistant nephrotic syndrome (SRNS) onset in the first year of life, disorders of sex development (DSD), and a predisposition to Wilms tumor (WT). Currently, a paradigm shift acknowledges a diverse spectrum of presentations beyond traditional syndromic definitions. Consequently, the concept of WT1-related disorders becomes more precise. A genotype-phenotype correlation has been established, emphasizing that the location and type of WT1 mutations significantly influence the clinical presentation, the condition severity, and the chronology of patient manifestations. Individuals presenting with persistent proteinuria, with or without nephrotic syndrome, and varying degrees of kidney dysfunction accompanied by genital malformations should prompt suspicion of WT1 mutations. Recent genetic advances enable a more accurate estimation of malignancy risk in these patients, facilitating a conservative nephron-sparing surgery (NSS) approach in select cases, with a focus on preserving residual kidney function and delaying nephrectomies. Other key management strategies include kidney transplantation and addressing DSD and gonadoblastoma. In summary, recent genetic insights underscore the imperative to implement individualized, integrated, and multidisciplinary management strategies for WT1-related disorders. This approach is pivotal in optimizing patient outcomes and addressing the complexities associated with these diverse clinical manifestations.
<P>PROBLEM TO BE SOLVED: To obtain a collagen synthesis inhibitor which does not affect the proliferation of cells and has high safety.  <P>SOLUTION: It was found that short chain peptides containing glycine and proline had a selective collagen synthesis-inhibiting effect. When the effects of these peptides on the proliferation of cells was examined, the peptides specifically inhibited only the synthesis of collagen without affecting the proliferation of cells. Further, in a cirrhosis rat model, the peptides improved serum GOT (glutamic oxalacetic transaminase) and GPT (glutamic pyruvate transaminase) values and inhibited the deposition of live collagen. It is considered that the identified peptides can be used as collagen synthesis inhibitors, and especially are useful as medicines which are used for preventing and treating fibrosed diseases including cirrhosis and little produce side effects.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
We will enroll 50 children to determine whether the PREMED method is non-inferior to the PREMIX method. We based our sample size on the outcome of pain and distress associated with the administration of IN midazolam, which will be measured using our primary outcome measure of the Observational Scale of Behavioral Distress-Revised (OSBD-R). The OSBD-R is an observational measure of distress that has been well validated in the pediatric population for evaluating painful and distressing procedures, and has been used in children as young as 1 year of age \[1,2\]. The sample size of 50 patients was determined based on a prestated margin of non-inferiority (delta) of 1.8 (SD 2.25). This value was based on the minimum clinically significant differences used in prior studies of painful procedures in children in the emergency department \[3,4,5\]. To determine noninferiority using a delta of 1.80 (SD 2.25), with a 1-tailed alpha of 0.025 and power of 80%, we would require 25 patients in each arm, for a total of 50 patients. OSBD-R scores will be determined independently by two blinded trained assessors who will review the videotapes of the study procedures. Interrater reliability of the OSBD-R between the two assessors will evaluated by determining the intraclass correlation coefficient. The period of administration of the midazolam alone in the PREMED group and the period of administration of the midazolam/lidocaine mixture in the PREMIX group are the two phases which will be compared to each other to determine our primary outcome.

Secondary outcome measures of pain and distress associated with IN midazolam administration will include the Children's Hospital of Eastern Ontario Pain Scale (CHEOPS); the Faces-LegsActivity-Crying-Consolability (FLACC) scale; and cry duration. These are all continuous measures that will be analyzed using the independent samples t-test.We will also evaluate parental and provider satisfaction across various domains using a 5-point Likert scale (see attached document for questions to be asked). Responses will be dichotomized into "agree" (i.e. if respondent answers "agree" or "strongly agree") or "disagree" (i.e. if respondent responds "undecided", "disagree", or "strongly disagree") and analyzed using the chi square test.
Participants receive retinoid 9cUAB30 PO QD on days 1 and 8-36. Treatment continues in the absence of unacceptable toxicity.
Drug development is a long and costly process, often limited by the toxicity and adverse drug reactions (ADRs) caused by drug candidates. Even on the market, some drugs can cause strong ADRs that can vary depending on an individual polymorphism. The development of Genome-wide association studies (GWAS) allowed the discovery of genetic variants of interest that may cause these effects. In this study, the objective was to investigate a deep learning approach to predict genetic variations potentially related to ADRs. We used single nucleotide polymorphisms (SNPs) information from dbSNP to create a network based on ADR-drug-target-mutations and extracted matrixes of interaction to build deep Neural Networks (DNN) models. Considering only information about mutations known to impact drug efficacy and drug safety from PharmGKB and drug adverse reactions based on the MedDRA System Organ Classes (SOCs), these DNN models reached a balanced accuracy of 0.61 in average. Including molecular fingerprints representing structural features of the drugs did not improve the performance of the models. To our knowledge, this is the first model that exploits DNN to predict ADR-drug-target-mutations. Although some improvements are suggested, these models can be of interest to analyze multiple compounds over all of the genes and polymorphisms information accessible and thus pave the way in precision medicine.
This arm aims to have 30 participants with a pharmacological manipulation. They will receive a reminder to reactivate their memory of a misophonia trigger followed by ingestion of a propranolol hydrochloride tablet.
OBJECTIVE: This metanalysis aims to assess the efficacy and safety of biliary stenting along with radiofrequency ablation compared with stents alone to treat malignant biliary obstruction (MBO) due to extrahepatic biliary strictures secondary to cholangiocarcinoma, pancreatic cancer, and metastatic cancer.
METHODS: A systemic search of major databases through April 2022 was done. All original studies were included comparing radiofrequency ablation with stenting versus stenting alone for treating malignant biliary strictures. The primary outcomes of interest were the difference in the mean stent patency and overall survival (OS) days between the 2 groups. The secondary outcome was to compare the adverse events of the 2 groups. The mean difference in the stent patency and OS days was pooled by using a random-effect model. We calculated the odds ratio to compare the adverse events between the 2 groups.
RESULTS: A total of 13 studies with 1339 patients were identified. The pooled weighted mean difference in stent patency was 43.50 days (95% CI, 25.60-61.41), favoring the RFA plus stenting. Moreover, the pooled weighted mean difference in OS was 90.53 days (95% CI, 49.00-132.07), showing improved survival in the RFA group. Our analysis showed no statistically significant difference in adverse events between the 2 groups OR 1.13 (95% CI, 0.90-1.42).
CONCLUSION: Our analysis showed that RFA, along with stent, is safe and is associated with improved stent patency and overall patient survival in malignant biliary strictures. More robust prospective studies should assess this association further.
Dihydroergotamine binds with high affinity to 5-HT1Dα and 5-HT1Dβ receptors. It also binds with high affinity to serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors, noradrenaline α2A, α2B and α1 receptors, and dopamine D2L and D3 receptors.

The therapeutic activity of dihydroergotamine in migraine is generally attributed to the agonist effect at 5-HT1D receptors. Two current theories have been proposed to explain the efficacy of 5-HT1D receptor agonists in migraine. One theory suggests that activation of 5-HT1D receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache. The alternative hypothesis suggests that activation of 5-HT1D receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release. In addition, dihydroergotamine possesses oxytocic properties..
This is a randomized, double-blinded study. Neither the patient nor the anesthesia practitioner advancing the ETT will know the group to which the patient has been assigned. On the day of surgery, participants will be randomized 1:1 to one of two groups. Both groups will be electively intubated with a fiberoptic scope. One group will be intubated using a Parker-Flex endotracheal tube and the second group of will be intubated with a standard endotracheal tube. There will be an equal probability of being assigned to either group. No placebo or control group will be used. Randomization will be computer-generated and assignments will be enclosed in sealed envelopes to provide allocation concealment. The anesthesiology technician involved in the case will open the envelope at the start of the case and will not be blinded to the study, due to the fact that the technician must prepare the endotracheal tube for the fiberoptic intubation.
Normal cognition will be defined as cognitive performance on detailed neuropsychometric testing that falls within 1 SD of age-, gender-, and education-matched norms in all cognitive domains, and no subjective report of cognitive decline from an individual's baseline (i.e. CDR 0). All participants in this group will undergo clinical and cognitive evaluations, CSF analysis, and functional MRI during resting state and semantic memory tasks.
NEW MATERIAL:A piperazine acetamide derivative of formula I (R1 is lower alkyl; R2 is phenyl or pyridyl; R3 is H or lower alkoxy) and its acid addition salt. EXAMPLE:4-Methyl-N-[2-(2-pyridylmethylaminocarbonyl)phenyl]-1-piperazine acetamide fumaric acid salt. USE:Useful as a remedy for urinary tract disorder. It exhibits excellent micturi tion reflex suppressing action and is effective in curing urinary tract disorder such as pollakiuria, feeling of residual urine, etc. PREPARATION:The compound of formula I can be produced by reacting a halogenoacetamide derivative of formula II (X is halogen) with an N- alkylpiperazine of formula III in a solvent such as benzene at a temperature between room temperature and the refluxing temperature of the solvent. The starting compound of formula II is also novel and can be synthesized by the reaction shown in the reaction formula.
An extraction method of patinopecten yessoensis polysaccharide comprises process steps of raw material treatment, homogenization, supersonic treatment, enzymolysis, separation, concentration, precipitation with alcohol, and drying. As for said raw material treatment, patinopecten yessoensis meat tissue is directly homogenized by adding water or homogenized by adding water after being oven dried or freeze dried; said enzymolysis is preformed with one or two of pepsin, trypsase, Bacillus subtilis neutral proteinase. Said meat tissue is scallop meat, scraps other than scallop meat, partial scraps, rod shaped scallop meat and partial scraps or all meat tissue other than shell. There is provided a process of extracting polysaccharide from patinopecten yessoensis, particularly from patinopecten yessoensis scraps with taking full advantage of scraps. The product obtained has high purity, and high yield. The patinopecten yessoensis polysaccharide produced can be used as either a single product or a base material which is combined with other food to give various multifunctional food.
BACKGROUND: Although whole blood (WB) transfusion was reported to improve survival in trauma patients with hemorrhagic shock, little is known whether a higher proportion of WB is associated with an improved survival. This study aimed to evaluate the association between whole blood ratio (WBR) and the risk of mortality in trauma patients requiring massive blood transfusion.
METHODS: We performed a retrospective cohort study from the ACS-TQIP between 2020 and 2021. Patients were aged ≥ 18 years and received WB within 4 h of hospital arrival as a part of massive blood transfusion. Study patients were categorized into four groups based on the quartiles of WBR. Primary outcome was 24-h mortality and secondary outcome was 30-day mortality. Multivariable logistic regression analysis, fitted with generalized estimating equations, was performed to adjust for confounding factors and accounted for within-hospital clustering.
RESULTS: A total of 4087 patients were eligible for analysis. The median age was 37 years (interquartile range [IQR]: 27-53 years), and 85.0% of patients were male. The median number of WB transfusions was 2.3 units (IQR 2.0-4.0 units), and the total transfusion volume was 4940 ml (IQR 3350-8504). When compared to the lowest WBR quartile, the highest WBR quartile had lower adjusted 24-h mortality (adjusted odds ratio [AOR]: 0.61, 95% confidence interval [CI]: 0.46-0.81) and 30-day mortality (AOR 0.58; 95% CI 0.45-0.75).
CONCLUSION: The probability of mortality consistently decreased with higher WBR in trauma patients requiring massive blood transfusion.
1,195,096. Tricyclic ketones. SANDOZ Ltd. 9 Oct., 1967 [4 Nov., 1966; 23 Jan., 1967; 12 June, 1967], No. 46012/67. Heading C2C. Novel compounds V wherein R signifies C 1-4  alkyl, R 3  signifies H or Ph, X signifies H or halogen and Y signifies O or S, are obtained: by treating a compound VII (obtained by nitrosation of a compound IX) or a compound VIII with an R.CO-alkanoylating agent in the presence of a hydrohalic acid to afford compounds V in which Y signifies O; thiation of compounds V in which Y is O affords corresponding compounds V in which Y is S. Compounds IX wherein X signifies 1- or 3- chloro (obtained by chlorination) are characterized as the corresponding oximes. Pharmaceutical preparations showing, in particular, tranquilizing and anti-inflammatory activity contain as active ingredient compounds V; administration is orally or parenterally.
The invention discloses a brewing method for pricklyash peel and acanthopanax selenium-rich medicinal wine. The method comprises the five procedures of formulating a formula for the selenium-rich medicinal wine, purchasing raw materials, processing the raw materials, brewing the medicinal wine and packaging finished medicinal wine. According to the formula formulated for the selenium-rich medicinal wine, 50 g of pricklyash peel, 200 g of acanthopanax, selenium malt with the amount equivalent to 1 mg of selenium, and 1,000 ml of millet wine are adopted. According to raw material purchasing, firstly, the amount of selenium-rich medicinal wine to be brown is determined, then, the purchase quantity of each traditional Chinese medicine decoction piece is converted according to the selenium-rich medicinal wine formula, and purchasing is conducted according to varieties. According to raw material processing, except for the millet wine, the purchased pricklyash peel, the purchased acanthopanax and the purchased selenium malt are sorted and crushed into medicine powder through a crusher with a 0.2-centimeter grain size sieve. According to selenium-rich medicinal wine brewing, the standby medicine powder is packaged into a glass bottle special for medicinal wine brewing, then the millet wine is packaged, sealed soaking is conducted for 2 weeks or above, and during brewing, stirring or vertically inverted shaking is conducted once every day so that uniform brewing can be conducted. According to finished medicinal wine packaging, when the brewing expires, filtering, deslagging, packaging and sealing are conducted, and 15-20 ml of the finished medicinal wine is drunk each time for two times every day.
BXCL501 is a thin film formulation of dexmedetomidine (DEX) for sublingual (SL) administration. The product is a small, solid-dose film formulation, approximately 286 mm2 in area and 0.7 mm thick, designed to solubilize in the SL space within 1-3 minutes. At the time of dosing, subjects will be verbally instructed on how to take the investigational product sublingually, and that they should retain the investigational product in the sublingual cavity until dissolved.
Participants will receive a daily HrQoL questionnaire on their personal smartphone using the docdok health application during 3 months. A selection of participants will furthermore receive a custom-built home disease monitoring device during 1 month. Both procedures start at least 4 weeks after hospital discharge.
Participants will receive RO6958688 weekly (QW) at escalating doses starting at 5 mg, in combination with a fixed dose (1200 mg) of atezolizumab every 3 weeks (Q3W). RO6958688 dosage will not exceed the MTD if defined in the BP29541 study.
PURPOSE:To obtain an antitumor substance, by heat-treating a glycoprotein part contained in rice bran or the residue after heat extraction of the rice bran with an alkali in an organic solvent and extracting the insoluble substance with water. CONSTITUTION:A hot water-soluble content (mainly polysaccharides) is removed from rice bran. Then an aqueous alkali solution-soluble content in the bran is extracted, an organic solvent is added, harmful polysaccharide such as hemilose, is removed, the residue is neutralized with an acid and RBF-P which is a glycoprotein part is collected. When the RBF-P is collected, fatty acid and lipid contained in RBF-P is preferably extracted with an organic solvent such as ether. The RBF-P after extraction is mixed with an alcohol and alkali such as sodium hydroxide or potassium hydroxide and heat-treated to provide an insoluble precipitate, which is then centrifuged and water is added to the precipitate and the mixture is stirred and heat-treated. The residue is removed and the resultant solution is purified and freeze-dried, etc., to provide the aimed antitumor substance which is dried powder.
This study aimed to evaluate the blood bacterial microbiota in healthy and febrile cats. High-quality sequencing reads from the 16S rRNA gene variable region V3-V4 were obtained from genomic blood DNA belonging to 145 healthy cats, and 140 febrile cats. Comparisons between the blood microbiota of healthy and febrile cats revealed dominant presence of Actinobacteria, followed by Firmicutes and Proteobacteria, and a lower relative abundance of Bacteroidetes. Upon lower taxonomic levels, the bacterial composition was significantly different between healthy and febrile cats. The families Faecalibacterium and Kineothrix (Firmicutes), and Phyllobacterium (Proteobacteria) experienced increased abundance in febrile samples. Whereas Thioprofundum (Proteobacteria) demonstrated a significant decrease in abundance in febrile. The bacterial composition and beta diversity within febrile cats was different according to the affected body system (Oral/GI, systemic, skin, and respiratory) at both family and genus levels. Sex and age were not significant factors affecting the blood microbiota of febrile cats nor healthy ones. Age was different between young adult and mature adult healthy cats. Alpha diversity was unaffected by any factors. Overall, the findings suggest that age, health status and nature of disease are significant factors affecting blood microbiota diversity and composition in cats, but sex is not.